SWP
ALNY icon

Sagespring Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sagespring Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$379K Buy
1,144
+8
+0.7% +$2.72K 0.01% 575
2025
Q4 		$452K Sell
1,136
-151
-12% -$66.8K 0.01% 503
2025
Q3 		$587K Buy
1,287
+371
+41% +$151K 0.01% 425
2025
Q2 		$299K Buy
+916
New +$253K 0.01% 582

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sagespring Wealth Partners's ALNY Position: Q1 2026 in Review

Sagespring Wealth Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 0.7% in Q1 2026, buying an estimated $2.72K and bringing the position to 1,144 shares worth $379K. The position accounts for 0.01% of the portfolio, ranked #575.

Sagespring Wealth Partners first reported a position in ALNY in Q2 2025 and has held it in 4 quarters since. The position peaked at $587K in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Sagespring Wealth Partners held 1,144 shares of Alnylam Pharmaceuticals worth $379K as of Q1 2026.
  • Sagespring Wealth Partners bought 8 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.72K.
  • Alnylam Pharmaceuticals made up 0.01% of Sagespring Wealth Partners's portfolio in Q1 2026, its #575 holding.
  • Sagespring Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Sagespring Wealth Partners's Alnylam Pharmaceuticals position peaked at $587K in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Sagespring Wealth Partners's 13F filing for Q1 2026, filed 7 May 2026.